GLP-1 Pharma Manufacturing Jobs 2026: The Complete Interview Guide

GLP-1 pharma manufacturing jobs 2026 are the hottest hiring story in the life sciences industry right now, and the numbers behind it are almost hard to believe. Novo Nordisk and Eli Lilly, the two companies that make Ozempic, Wegovy, Mounjaro, and Zepbound, have collectively committed more than $30 billion to new and expanded manufacturing capacity since 2023, and most of that money is landing in 2026 in the form of qualified openings for engineers, quality professionals, and production staff. If you work in pharmaceutical manufacturing, biologics, vaccines, or any adjacent injectable-drug field, this is the hiring wave to understand and prepare for, whether you are targeting a site in Indiana, North Carolina, Denmark, Belgium, or Italy, or hoping that the boom eventually pulls you into a CDMO role closer to home.

This guide walks through the landscape driving the boom, the specific roles in highest demand, the interview questions these companies are actually asking, a prep plan you can follow in under a month, and the mistakes that trip up otherwise strong candidates. It is written for a global audience, because this expansion is not a single-country story. It is happening simultaneously across the US Midwest and Southeast, Scandinavia, and Western Europe, and it is reshaping hiring at the contract manufacturers and suppliers that feed into these companies everywhere, including India.

The GLP-1 manufacturing boom, by the numbers

The scale of investment in GLP-1 production capacity over the past two years is genuinely unusual for the pharmaceutical industry, where new-plant announcements are typically measured in hundreds of millions, not billions.

The starting point is Novo Holdings' roughly $16.5 billion acquisition of Catalent, the contract development and manufacturing organization (CDMO) that had been running fill-finish operations for Novo Nordisk under contract. As part of that deal, Novo Nordisk itself paid $11 billion to acquire three specific Catalent sites outright: a sterile fill-finish plant in Bloomington, Indiana; another in Brussels, Belgium; and a third in Anagni, Italy. Together those three sites employ more than 3,000 people and are dedicated almost entirely to filling and finishing Wegovy and Ozempic, according to reporting from European Pharmaceutical Review. That single transaction converted three CDMO sites that used to serve many pharma clients into dedicated GLP-1 production hubs, which is exactly why hiring at all three has accelerated: dedicated single-product plants need to ramp output fast, and ramping output means headcount.

Eli Lilly has taken a build-rather-than-buy approach, but at similar scale. Its flagship site in Lebanon, Indiana, has seen its investment more than double, growing from an initial $3.7 billion commitment to more than $9 billion in total after an additional $5.3 billion was announced, according to FiercePharma. That site is dedicated to producing the active pharmaceutical ingredient (API) for tirzepatide, the molecule behind both Mounjaro and Zepbound. Roughly 900 people are expected to work there once it is fully operational, with the new investment alone adding about 200 skilled roles for engineers, scientists, and lab technicians.

Lilly has also doubled its investment at its Concord, North Carolina, facility from $1 billion to $2 billion. That plant, which came online in 2024 to relieve bottlenecks in injectable GLP-1 production, is expected to employ around 600 people at full capacity, with roughly two-thirds of those positions already filled as of the most recent reporting from Healthcare Packaging.

On top of the North American build-out, Novo Nordisk is pouring roughly $6 billion into a new active pharmaceutical ingredient facility in Kalundborg, Denmark, a 170,000 square meter plant dedicated to producing semaglutide, the API in both Ozempic and Wegovy. That project is expected to create around 800 jobs once fully operational later in the decade, but hiring for engineering, validation, and start-up roles is already ramping in 2026 as construction and commissioning proceed.

Add it up and you get a genuinely global map of new GLP-1 manufacturing capacity: Indiana (two separate mega-sites), North Carolina, Denmark, Belgium, and Italy, plus a widening ring of suppliers, packaging partners, and CDMOs that support all of them.

Why the job market is booming and shrinking at the same time

Here is the nuance that a lot of candidates miss, and it matters for how you frame your interview answers: this is not a story of uniform growth across the pharmaceutical industry. It is a story of concentrated, aggressive growth in manufacturing, quality, and production roles tied directly to GLP-1 drugs, happening at the same time that Novo Nordisk has cut roughly 9,000 jobs elsewhere in the business.

In September 2025, Novo Nordisk announced a global restructuring that eliminated about 9,000 positions, roughly 11% of its workforce, including 5,000 roles in Denmark, according to CNBC. The cuts came as new CEO Mike Doustdar moved to protect margins amid intensifying US competition from Eli Lilly, the rise of cheaper compounded GLP-1 alternatives, and pricing pressure in core markets. Novo Nordisk itself has said the restructuring is meant to sharpen focus on diabetes and obesity as growth priorities, not retreat from them, and the company has been explicit that manufacturing and supply capacity for Wegovy and Ozempic remain protected and expanding even as corporate, commercial, and some R&D functions shrink.

What this means practically: if you are interviewing for a GLP-1 manufacturing role in 2026, you should expect interviewers to be direct about the fact that headcount growth is targeted, not general. They are hiring aggressively for fill-finish technicians, process engineers, validation specialists, and quality staff at specific dedicated sites, while simultaneously running a leaner corporate structure everywhere else. Knowing this distinction, and being able to speak to why you specifically fit the manufacturing and quality side of the business rather than a generic pharma career narrative, is a small but real signal of preparation.

Where the jobs are: the new GLP-1 manufacturing map

United States: Indiana and North Carolina

Indiana has become the unofficial capital of GLP-1 manufacturing in the US. Eli Lilly's Lebanon campus (API and advanced therapy manufacturing) and Novo Nordisk's Bloomington fill-finish site sit within the same state, both scaling headcount through 2026 and beyond. Indiana's state economic development agency has actively courted this investment with incentive packages, and the result is a genuine regional cluster effect: contract manufacturers, packaging suppliers, and specialty logistics firms are opening satellite operations nearby to serve both companies.

North Carolina is the second US hub, anchored by Lilly's Concord facility, which focuses on injectable device and fill-finish work for Mounjaro and Zepbound. The Research Triangle area already had a deep bench of pharma manufacturing talent from established players, which is part of why Lilly chose it, and that existing talent pool means competition for roles here can be sharper than in newer-build markets.

Europe: Denmark, Belgium, and Italy

Denmark is Novo Nordisk's home base and the site of its largest single capital project, the roughly $6 billion Kalundborg API expansion. Belgium (Brussels) and Italy (Anagni) are the two European fill-finish sites that came over in the Catalent transaction; both were established CDMO operations before the acquisition, so they already have trained aseptic processing workforces, and current hiring there is about scaling existing teams and transferring institutional knowledge from serving multiple clients to running single-product, high-volume lines.

What this means if you're based in India or elsewhere

None of the newly announced mega-sites are in India, but the boom still matters enormously for Indian pharma and CDMO professionals. India's contract manufacturing and API sector is a major supplier into the global GLP-1 supply chain, and Indian companies are racing to build peptide synthesis and fill-finish capacity of their own to capture overflow demand and eventually compete on biosimilar and generic GLP-1 versions once patents lapse. Experience with aseptic processing, validation, or regulatory submissions gained at an Indian CDMO or API manufacturer is directly relevant background for interviews at the multinational sites described above, and increasingly for roles at the Indian companies building their own GLP-1 capacity. If you want a companion read focused specifically on India's healthcare and pharma interview landscape, including clinical, QA, and pharmacovigilance roles, see our guide to healthcare and pharma interview questions in India.

The roles driving the GLP-1 hiring wave

Manufacturing and process engineers

These are the engineers who own how the drug substance and drug product actually get made and moved through the plant: designing and troubleshooting process steps, running scale-up from pilot to commercial batches, and closing the gap between what the process was validated to do and what actually happens on the floor. GLP-1 sites need people who understand continuous or high-throughput batch production for peptide and biologic APIs, not just small-molecule tablet lines.

Quality assurance and quality control specialists

QA owns the systems, documentation, deviations, and batch release decisions that keep a GMP site audit-ready. QC runs the lab testing, in-process checks, and stability programs that confirm each batch meets specification. Demand for both has spiked because dedicated single-product plants running near capacity generate a constant stream of deviations, change controls, and investigations that need experienced hands to close out quickly without compromising compliance.

Validation engineers

Validation is arguably the single hottest sub-specialty in this hiring wave. Every new line, every piece of equipment, every cleaning procedure, and every software system at a new or expanded GLP-1 site needs to go through installation, operational, and performance qualification (IQ/OQ/PQ) before it can be used for commercial production. Sites that are literally standing up new capacity in 2026, like Lebanon and Kalundborg, need large validation teams just to get equipment qualified fast enough to hit their production targets.

Fill-finish and aseptic processing technicians

This is the largest single category of new headcount at the Catalent-derived sites and at Lilly's device-focused plants. Fill-finish technicians run the aseptic filling lines that put liquid drug product into pens, vials, or prefilled syringes, under strict sterility controls. Demand ranges from entry-level line operators to senior aseptic processing specialists who can troubleshoot isolator and filling-line issues without ever breaking sterility.

Supply chain and biologics production roles

Because GLP-1 demand has repeatedly outstripped supply since 2022, supply chain planning has become a genuinely strategic function rather than a back-office one. Sites need planners and production schedulers who understand cold-chain logistics for injectable biologics, raw material sourcing for peptide synthesis, and capacity allocation across multiple product presentations (pens, vials, oral formulations).

Regulatory affairs specialists

Regulatory teams manage the submissions, site transfer filings, and health authority interactions needed every time capacity moves or expands, which is happening constantly right now. Experience with FDA, EMA, or other major-market submissions for injectable or biologic products is in high demand, especially people who have handled manufacturing site addition or technology transfer filings before.

What GLP-1 manufacturers actually look for in interviews

Across all of these roles, hiring managers at Lilly, Novo Nordisk, and their CDMO partners are consistently screening for the same handful of things, regardless of job title:

• Real GMP fluency, not textbook GMP. They want to hear how you personally handled a deviation, a CAPA (corrective and preventive action), or an audit finding, not a definition of Good Manufacturing Practice.
• Genuine aseptic processing exposure. For fill-finish and related roles, interviewers probe hard on sterile technique, contamination control, and how you behave when something goes wrong inside a cleanroom or isolator.
• Process validation and tech transfer experience. Because so many of these sites are new or newly repurposed, the ability to talk through IQ/OQ/PQ, technology transfer between sites, or scale-up from lab to commercial batch size is a major differentiator.
• Scale-up judgment. These plants are trying to hit aggressive volume targets. Interviewers want evidence you can reason about throughput, yield, and capacity constraints, not just execute a fixed procedure.
• Safety and quality culture fit. Because these are high-volume, high-visibility, patient-facing products (often used by patients managing serious health conditions), companies are explicit about wanting people who treat safety and compliance as non-negotiable, not as friction to work around.

GLP-1 manufacturing interview questions and how to answer them

GMP and regulatory knowledge questions

"Walk me through how you would handle an out-of-specification (OOS) result during a batch release." Strong answers describe a structured investigation: quarantine the batch, document the deviation immediately, distinguish assignable cause from a true product failure, involve QA and QC in parallel, and follow your site's CAPA process through to closure with a documented rationale. Naming the framework (deviation, root cause analysis, CAPA, effectiveness check) signals real experience.

"How do you stay current on evolving FDA or EMA guidance for injectable biologics?" Interviewers are checking whether you treat regulatory awareness as a habit rather than a task assigned to someone else. A good answer mentions specific channels, such as FDA guidance documents, EMA scientific advice, or internal regulatory intelligence functions, and gives an example of a guidance change that affected your past work.

Aseptic processing and sterile fill-finish questions

"Describe a time you identified a potential contamination risk before it became a problem." This is asked almost verbatim across fill-finish interviews. Use a specific, concrete example: what you noticed (an environmental monitoring excursion, an operator technique issue, an equipment alarm pattern), what you did immediately, and how you prevented recurrence.

"What's your experience with isolators versus RABS (restricted access barrier systems)?" You do not need deep expertise in both, but you should be able to describe the systems you have worked with, the tradeoffs between them (isolator systems offer stronger sterility assurance but less operator flexibility; RABS offer more flexibility with slightly higher contamination risk), and how you adapted your practice to the system in front of you.

Process validation and scale-up questions

"How would you validate a new fill-finish line before it goes into commercial production?" Structure your answer around the IQ/OQ/PQ lifecycle: confirming the equipment is installed correctly, that it operates within specified parameters, and that it performs consistently under real production conditions across multiple runs. Mention how you would define acceptance criteria up front and involve QA in protocol approval.

"Tell me about a time you scaled a process from pilot to commercial batch size. What changed, and what surprised you?" This question tests judgment, not memorization. Good answers acknowledge that scale-up rarely goes exactly as modeled, describe one concrete deviation between predicted and actual performance (mixing time, heat transfer, fill accuracy), and explain how you resolved it.

Safety culture and behavioral questions

"Tell me about a time you had to stop or slow down production because of a safety or quality concern, even under schedule pressure." This is one of the most important questions in the entire interview, because it directly tests whether you will protect patients and compliance when a plant is under pressure to hit volume targets, which every GLP-1 site currently is. Use a real, specific example with a clear outcome, and be honest about the tension you felt between speed and safety.

"How do you handle disagreement with a supervisor about whether something meets specification?" Interviewers want to see that you can escalate professionally through the right channels (QA, deviation process, documented rationale) rather than either silently complying or going around the chain of command.

For a structured way to practice answering behavioral and technical questions like these out loud before the real interview, ClavePrep's STAR answer builder is built specifically to help you turn a rough example into a tight, structured response.

A practical 3-week prep plan

Week one: rebuild your technical foundation. Review current GMP fundamentals, refresh your understanding of aseptic processing principles if you are targeting fill-finish or QA roles, and read the actual FDA or EMA guidance documents relevant to injectable biologics manufacturing if you have not looked at them recently. Skim recent industry coverage of the specific site or company you are targeting (Bloomington, Lebanon, Concord, Kalundborg, Brussels, or Anagni) so you can speak knowledgeably about what that plant actually produces and where it is in its build-out.

Week two: build your story bank. Pull together five to seven concrete examples from your career: a deviation you resolved, a validation project you led or supported, a scale-up you were part of, a safety call you made under pressure, and a time you worked cross-functionally with QA or regulatory. Write each one out using a clear structure (situation, task, action, result), because these companies interview heavily behaviorally even for highly technical roles. This is exactly the kind of prep ClavePrep's interview practice tools are designed for, letting you rehearse full mock interviews against realistic GLP-1 manufacturing-style questions.

Week three: rehearse out loud and tighten your narrative. Practice answering the technical and behavioral questions above out loud, not just in your head. Time yourself. Cut any answer running past two minutes down to its essential structure. If you are coming from an adjacent industry, spend extra time rehearsing the "translation" answers described below, since that framing rarely comes naturally without practice. If you are new to structuring interview answers generally, our how it works page walks through ClavePrep's approach to building and practicing those answers before the real conversation.

How to reposition experience from adjacent industries

A large share of the people who will get hired into this wave are not coming from a GLP-1 or even a diabetes-drug background. They are coming from vaccines, monoclonal antibody biologics, other injectable small molecules, or general sterile manufacturing. That is a strength, not a weakness, if you frame it correctly.

The translation move that works: identify the underlying technical skill that transfers, and say so explicitly, rather than assuming the interviewer will connect the dots. If you validated a vaccine fill line, say directly: "the IQ/OQ/PQ process I ran for a vaccine filling line maps closely onto what a GLP-1 pen or vial line requires, the core difference being viscosity and cold-chain handling for the peptide formulation." If you worked in monoclonal antibody production, note that peptide APIs share meaningful process chemistry and purification logic with biologics, even though GLP-1 drugs are technically small peptides rather than large proteins. If your aseptic processing background comes from a generic injectable small-molecule plant, emphasize that sterile technique, environmental monitoring, and contamination control principles are largely product-agnostic, and give a specific example proving you can pick up a new formulation quickly.

Avoid the opposite mistake: downplaying your adjacent-industry background as if it is a liability to be apologized for. Hiring managers know they cannot fill every GLP-1 role with people who have literally worked on Ozempic before, because that pool is small and mostly already employed. What they are actually screening for is whether your underlying skill set transfers and whether you can articulate that transfer clearly and confidently.

Common mistakes candidates make

Treating it as one undifferentiated "pharma boom." Interviewers can tell quickly if you have not looked into the specific site, product, and stage of build-out you are interviewing for. Kalundborg's API expansion, Lebanon's tirzepatide API campus, and the Bloomington or Brussels fill-finish operations are different operations with different technical demands; generic answers read as generic.

Underestimating the behavioral component. Because these are technical roles, candidates sometimes over-prepare on process chemistry and engineering and under-prepare on the safety-culture and escalation questions that these companies weight heavily, precisely because they are hiring at volume and speed and need to trust judgment under pressure.

Failing to acknowledge the restructuring context. If asked about job security or company direction, particularly at Novo Nordisk given the 2025 layoffs, avoid pretending you are unaware of it. A brief, confident acknowledgment that you understand the company is concentrating investment in manufacturing and production while streamlining elsewhere, and that this is exactly the growth area you want to be part of, reads as informed rather than naive.

Not quantifying scale-up or validation experience. Vague statements like "I have validation experience" undersell you compared to a specific answer: how many protocols, what equipment, what timeline, what was the outcome.

Ignoring the geographic dimension. If you are interviewing for a specific site, know roughly what that site produces, its approximate size and headcount trajectory, and any recent public news about it. It takes fifteen minutes of reading and it is one of the easiest ways to stand out.

Getting the technical answers right matters, but so does sounding rehearsed rather than reading from a script. Running a few mock interview sessions against realistic questions before the real thing, using a structured practice tool rather than just reading questions off a list, is one of the highest-leverage things you can do in the final week before an interview for a role like this.

Frequently asked questions

What companies are hiring for GLP-1 manufacturing jobs in 2026? Eli Lilly and Novo Nordisk are the two primary drug manufacturers driving direct hiring, at sites including Lebanon and Bloomington, Indiana; Concord, North Carolina; Kalundborg, Denmark; and Brussels, Belgium, and Anagni, Italy. Beyond the two originator companies, CDMOs, packaging suppliers, cold-chain logistics firms, and specialty equipment vendors that serve these sites are also hiring at pace, along with API and peptide suppliers globally, including in India.

Do I need direct GLP-1 or diabetes-drug experience to get hired? No. Most people entering this hiring wave are coming from adjacent backgrounds, including vaccines, monoclonal antibody biologics, and general sterile injectable manufacturing. What matters most is being able to clearly explain how your existing skills (aseptic processing, validation, GMP compliance) transfer to peptide and biologic production.

What is the salary range for GLP-1 manufacturing roles? Entry-level aseptic manufacturing and fill-finish technician roles in the US typically pay in the roughly $23 to $32 per hour range. Fill-finish and process engineers generally earn in the $43 to $62 per hour range, translating to roughly $90,000 to $130,000 annually depending on experience and location. Validation engineers average around $90,000 annually in the US, with GMP validation specialists earning between roughly $39 and $63 per hour. Senior and principal-level aseptic process engineering roles can reach $140,000 to over $250,000 annually. European salaries vary significantly by country and typically include stronger statutory benefits than US equivalents.

Why is Novo Nordisk cutting jobs while also hiring aggressively for manufacturing? Novo Nordisk's roughly 9,000-position restructuring in 2025 targeted corporate, commercial, and some R&D functions amid pricing pressure and rising US competition from Eli Lilly, while manufacturing and production capacity for Wegovy and Ozempic remained a stated growth priority. The two moves reflect the same underlying strategy: concentrate resources where demand is guaranteed (production of the drugs themselves) and reduce cost elsewhere.

Is this hiring boom relevant if I'm based in India? Yes, indirectly but significantly. India is a major hub for API synthesis, peptide manufacturing, and CDMO services that feed into the global GLP-1 supply chain, and Indian companies are actively building their own peptide and fill-finish capacity to serve both export demand and an eventual domestic and biosimilar market. Experience gained at Indian CDMOs and API manufacturers is directly relevant preparation for interviews with multinational GLP-1 manufacturers and their suppliers.

What's the difference between a validation engineer and a process engineer in this context? A process engineer designs, runs, and troubleshoots the actual manufacturing steps, focused on throughput, yield, and process performance. A validation engineer proves, through documented protocols (IQ/OQ/PQ), that equipment and processes consistently perform as intended before they are used for commercial production. Both roles are in extremely high demand right now because so many GLP-1 sites are new or newly expanded and need extensive qualification work before they can hit production targets.

How technical do interviews get for QA and regulatory affairs roles compared to engineering roles? QA and regulatory interviews tend to focus more on judgment, documentation discipline, and cross-functional communication than on deep process engineering detail, but they still expect fluency in GMP fundamentals, deviation and CAPA processes, and (for regulatory roles) familiarity with relevant FDA or EMA submission types. Expect fewer equipment-specific questions and more scenario-based questions about handling investigations, audits, or health authority interactions.

Should I mention the Novo Nordisk layoffs or industry pricing pressure if the interviewer doesn't bring it up? You do not need to raise it unprompted, but you should be prepared to answer confidently if it comes up, since interviewers sometimes test whether candidates understand the business context. A brief, informed answer that shows you understand the company is investing specifically in production capacity while managing costs elsewhere reads far better than acting surprised or unaware.

Whether you're targeting a fill-finish role in Bloomington, a validation position in Kalundborg, or a process engineering job at a CDMO supplying either company, the fastest way to close the gap between "qualified on paper" and "confident in the room" is structured practice. ClavePrep's interview preparation tools let you rehearse realistic technical and behavioral questions for manufacturing and quality roles, build tighter answers with the STAR builder, and walk in ready for one of the most active hiring booms in pharmaceutical manufacturing in a decade.